Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5 alpha Restrictive Macaques

Sudhir Kasturi, Emory University
Pamela A. Kozlowski, Louisiana State University
Helder Nakaya, Emory University
Matheus C. Burger, University of Sao Paulo
Pedro Russo, University of Sao Paulo
Matthew Pham, Emory University
Yevgeniy Kovalenkov, Emory University
Eduardo L. V. Silveira, Emory University
Colin Havenar-Daughton, La Jolla Institute of Allergy and Immunology
Samantha L. Burton, Emory University

Only first 10 authors above; see publication for full author list.

Journal Title: Journal of Virology
Volume: Volume 91, Number 4
Publisher: American Society for Microbiology | 2017-02-01
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1128/JVI.01844-16
Permanent URL: https://pid.emory.edu/ark:/25593/s4fx4

Final published version: http://dx.doi.org/10.1128/JVI.01844-16

Copyright information:
© 2017 American Society for Microbiology.
Accessed January 24, 2020 5:08 PM EST
Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques

Sudhir Pai Kasturi,a Pamela A. Kozlowski,b Helder I. Nakaya,a,c Matheus C. Burger,c Pedro Russo,c Mathew Pham,a Yevgeniy Kovalenkov,a Eduardo L. V. Silveira,a,c Colin Havenar-Daughton,d Samantha L. Burton,a Katie M. Kilgore,a Mathew J. Johnson,a Rafiq Nabi,b Traci Legere,a Zarpheen Jinnah Sher,a Xuemin Chen,a Rama R. Amara,a,d Eric Hunter,a,g Steven E. Bosinger,a Paul Spearman,a,e Shane Crotty,d Francois Villinger,a,h Cynthia A. Derdeyn,a,g Jens Wrammert,a,e Bali Pulendran,g

Emory Vaccine Center/Yerkes National Primate Research Center at Emory University, Atlanta, Georgia, USAa, Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, Louisiana, USA; Faculty of Pharmaceutical Sciences, Department of Clinical and Toxicological Analyses, University of Sao Paulo, Sao Paulo, Brazil; Division of Vaccine Discovery, La Jolla Institute of Allergy and Immunology, La Jolla, California, USA; Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA; Division of Microbiology and Immunology, Emory University; Rollins Research Center, Atlanta, Georgia, USA; Department of Pathology and Laboratory Medicine, Atlanta, Georgia, USA; New Iberia Research Center, University of Louisiana Lafayette, New Iberia, Louisiana, USAh

ABSTRACT Our previous work has shown that antigens adjuvanted with ligands specific for Toll-like receptor 4 (TLR4) and TLR7/8 encapsulated in poly(lactic-co-glycolic) acid (PLGA)-based nanoparticles (NPs) induce robust and durable immune responses in mice and macaques. We investigated the efficacy of these NP adjuvants in inducing protective immunity against simian immunodeficiency virus (SIV). Rhesus macaques (RMs) were immunized with NPs containing TLR4 and TLR7/8 agonists mixed with soluble recombinant SIVmac239-derived envelope (Env) gp140 and Gag p55 (protein) or with virus-like particles (VLPs) containing SIVmac239 Env and Gag. NP-adjuvanted vaccines induced robust innate responses, antigen-specific antibody responses of a greater magnitude and persistence, and enhanced plasmablast responses compared to those achieved with alum-adjuvanted vaccines. NP-adjuvanted vaccines induced antigen-specific, long-lived plasma cells (LLPCs), which persisted in the bone marrow for several months after vaccination. NP-adjuvanted vaccines induced immune responses that were associated with enhanced protection against repeated low-dose, intravaginal challenges with heterologous SIVsmE660 in animals that carried TRIM5α restrictive alleles. The protection induced by immunization with protein-NP correlated with the prechallenge titers of Env-specific IgG antibodies in serum and vaginal secretions. However, no such correlate was apparent for immunization with VLP-NP or alum as the adjuvant. Transcriptional profiling of peripheral blood mononuclear cells isolated within the first few hours to days after primary vaccination revealed that NP-adjuvanted vaccines induced a molecular signature similar to that induced by the live attenuated yellow fever viral vaccine. This systems approach identified early blood transcriptional signatures that correlate with Env-specific antibody responses in vaginal secretions and protection against infection. These results demonstrate the adjuvanticity of the NP adjuvant in inducing persis-
tent and protective antibody responses against SIV in RMs with implications for the design of vaccines against human immunodeficiency virus (HIV).

**IMPORTANCE** The results of the RV144 HIV vaccine trial, which demonstrated a rapid waning of protective immunity with time, have underscored the need to develop strategies to enhance the durability of protective immune responses. Our recent work in mice has highlighted the capacity of nanoparticle-encapsulated TLR ligands (NP) to induce potent and durable antibody responses that last a lifetime in mice. In the present study, we evaluated the ability of these NP adjuvants to promote robust and durable protective immune responses against SIV in nonhuman primates. Our results demonstrate that immunization of rhesus macaques with NP adjuvants mixed with soluble SIV Env or a virus-like particle form of Env (VLP) induces potent and durable Env-specific antibody responses in the serum and in vaginal secretions. These responses were superior to those induced by alum adjuvant, and they resulted in enhanced protection against a low-dose intravaginal challenge with a heterologous strain of SIV in animals with TRIM5a restrictive alleles. These results highlight the potential for such NP TLR L adjuvants in promoting robust and durable antibody responses against HIV in the next generation of HIV immunogens currently being developed.

**KEY WORDS** SIV, vaccine, rhesus macaques, TLR ligands, adjuvants, HIV vaccines, antibody responses, plasma cells, plasmablasts

Despite more than 3 decades of research since the discovery of human immunodeficiency virus type 1 (HIV-1), an AIDS vaccine remains elusive (1, 2). Initial strategies in HIV-1 vaccine development focused on the stimulation of antibody responses using the recombinant monomeric envelope (Env) gp120 protein immunogen (2). Subsequent strategies, such as the recombinant adenovirus type 5 (rAd5) vector approach, focused on eliciting antigen-specific CD8+ T cell responses (1). However, both strategies failed to demonstrate protection in clinical trials, and in fact, the rAd5 approach was reported to result in an enhancement of infection (3). Recently, a phase III clinical trial (the RV144 trial) of a vaccine reported that it yielded modest protective efficacy (~31%) (2, 4). Vaccination with isotype class-switched IgG antibodies specific to the V1/V2 region of HIV-1 gp120 correlated with a decreased risk of infection which waned with time, and vaccination with isotype class-switched IgA antibodies correlated with an increased risk of infection, highlighting a critical balance between the presence of IgG and IgA antibodies in the circulation (5). These results highlight the need to develop vaccines that induce antibody responses of potent magnitude and of a sufficient durability to protect against infection.

The induction of a strong and durable antibody response to vaccination is critically dependent on the use of effective adjuvants that stimulate the innate immune system (6, 7). Recent work in mice, nonhuman primates (NHPs), and humans has highlighted a new generation of molecular adjuvants targeted to pathogen recognition receptors (PRRs) on innate cells, such as dendritic cells (DCs) (8–11). Specific agonists of the Toll-like receptor (TLR) hold much promise as vaccine adjuvants. These adjuvants have, in fact, been licensed for clinical use and have been used in one of the vaccines against human papillomavirus. They are also being evaluated for use in other vaccine regimens against infections and cancers (8). Napolitani and colleagues demonstrated that specific combinations of TLR ligands induced a synergistic activation of cytokine production in human DCs in vitro (12). Consistent with this, our recent work demonstrated that the delivery of a specific combination of TLR ligands encapsulated in nanoparticles (NPs) with antigens induced enhanced DC activation and a synergistic increase in antigen-specific T cell and antibody responses in mice (13). A striking result to emerge from this study was that specific combinations of TLR ligands induced a greatly enhanced antibody response and long-lived germinal center (GC) responses similar to those observed in live viral infections (14). The observation that specific combinations of TLR ligands enhance antibody responses has been confirmed by recent studies (15–17).
These studies highlight the potential of NP-encapsulated TLR ligands to be vaccine adjuvants. In order to demonstrate this preclinically in an NHP model, we evaluated the immunogenicity of two distinct forms of simian immunodeficiency virus (SIV) strain SIVmac239 Env immunogens, a soluble Env protein form and a virus-like particle (VLP) form, each of which was administered with NP and alum adjuvants to rhesus macaques (RMs). Our data demonstrate that when the NP adjuvant is used with soluble Env, it induces robust and durable Env-specific antibody responses in serum and mucosal secretions that correlate with enhanced protection against an SIVsmE660 mucosal challenge. Furthermore, systems-based approaches delineated the novel molecular signatures associated with the enhanced immunogenicity and efficacy of the NP-adjuvanted vaccines.

**RESULTS**

**Experimental design.** Animals were allocated to four treatment groups, as described in Fig. 1A. Animals in groups 1 and 2 were immunized with an SIVmac239 VLP that contained Env (50 μg) and Gag (1,500 μg) mixed with the alum or NP adjuvant, respectively. Animals in groups 3 and 4 were immunized with a combination of SIVmac239-derived Env (50 μg) and Gag (50 μg) with alum or NP adjuvant, respectively. For brevity, here we refer to the treatments for groups 1 and 2 as VLP-NP and VLP-alum, respectively, and the treatments for groups 3 and 4 as protein-NP and protein-alum, respectively. Animals carrying either restrictive or permissive TRIM5α alleles were...
equally distributed in the treatment groups used in the study, as shown in Table S1 in the supplemental material. VLP integrity was assessed using transmission electron microscopy, and the amounts of Env as well as Gag in VLPs were quantified as shown in Fig. S1 and as described previously (18, 19). Due to the intrinsic stoichiometry of the Env and Gag amounts assembled in VLPs, the dose of Gag was 30-fold higher in groups 1 and 2 than groups 3 and 4. The NP adjuvant doses administered to the RMs (50 μg monophosphoryl lipid A [MPL], 750 μg TLR7/8 ligand R848) were those reported earlier (13), and alum was used at 500 μg following guidelines on the use of alum for preclinical evaluations (20–22). The timing of the vaccinations and immunological analyses is detailed in Fig. 1B.

NP-adjuvanted vaccines induce robust and persistent systemic antibody responses. The magnitude of the binding antibody response against SIVmac239 Env in serum was measured by enzyme-linked immunosorbent assay (ELISA) (Fig. 2A). Env-specific IgG responses were detected at 2 and 5 weeks after the primary immunization and were significantly boosted in all treatment groups after the second immunization. The resulting change in the magnitude of the antibody response at week 10 equaled 227-fold (protein-NP, Wilcoxon matched-pair signed-rank test, \( P = 0.0020 \)), 147-fold (VLP-NP, \( P = 0.0039 \)), 192-fold (VLP-alum, \( P = 0.0078 \)), and 69-fold (protein-alum, \( P = 0.0020 \)) in comparison with that at week 5. The overall response in the study peaked at week 27 (2 weeks after the final vaccination) and was significantly greater in animals vaccinated with protein-NP (titer, 680.77 μg/ml) than in animals vaccinated with (i) VLP-alum (titer, 19.81 μg/ml, 34.4-fold higher; \( P < 0.001 \), Kruskal-Wallis test followed by Dunn’s correction), (ii) VLP-NP (titer, 78.71 μg/ml, ~8.6-fold higher; \( P < 0.01 \)), and (iii) protein-alum (titer, 104.47 μg/ml, 6.5-fold higher; \( P \) was not significant). At week 41, the responses in animals vaccinated with protein-NP persisted at higher levels (titer, 37.24 μg/ml) than in animals vaccinated with (i) VLP-alum (titer, 1.81 μg/ml, 20.5-fold higher; \( P < 0.001 \), Kruskal-Wallis test followed by Dunn’s correction), (ii) VLP-NP (titer, 1.78 μg/ml; \( P < 0.0001 \), Kruskal-Wallis test followed by Dunn’s correction), and (iii) protein-alum (titer, 3.91 μg/ml; \( P < 0.05 \)) (Fig. 2B). Homologous Env-specific serum IgA responses were approximately 200-fold lower than the IgG responses but followed kinetics similar to those of the IgG responses, and IgA persisted at higher levels in animals that received protein-NP than in the other groups (Fig. S2A). At week 37 (4 weeks prior to challenge), persistent binding antibody responses capable of recognizing SIVsmE660 gp120 (Fig. 2C) and HIV-2 gp36, a protein that is highly homologous to SIVgp41 (Fig. 2D), were also observed.

Antibody effector functions are dependent on the antibody isotypes as well as glycosylation patterns (23), which could contribute to protective immunity (24). To assess the quality of the antibody responses, we measured antibody-dependent phago-cytic (ADP) responses (25). Consistent with the binding antibody responses, there was a significantly enhanced and persistent ADP response in animals immunized with protein relative to that in animals immunized with VLPs (Fig. 2E). Interestingly, similar to the binding antibody responses, higher neutralizing activity against tier 1 SIVsmE660.11 was observed in the serum of animals immunized with protein-NP than in the serum of animals in the other groups (Fig. 2F). However, negligible neutralization of the challenge stock of SIVsm660 was observed in all vaccine groups (Fig. S2B). These data demonstrate that the NP adjuvant enhances humoral immunity against SIV immunogens.
NP adjuvant induces robust Env-specific plasmablast responses in blood and induces long-lived plasma cell responses in bone marrow and draining lymph nodes (LNs). The recall antibody response to vaccination in humans is characterized by a striking increase in antigen-specific plasmablasts in the peripheral blood at 7 days postvaccination (26). There is a relative paucity of data on the kinetics of the plasmas...
last response in macaques (27). Interestingly, immunized RMs exhibited significant Env-specific plasmablast responses at day 4 that contracted significantly by day 7 (Fig. 3A and B). The frequencies of IgG-secreting Env-specific plasmablasts were higher than those of IgA- or IgM-secreting Env-specific plasmablasts. Consistent with the Env-specific antibody responses, immunization with protein-NP induced significantly higher frequencies of Env-specific plasmablasts than the other immunization modalities (Fig. 3C and S3A). Env-specific plasmablast responses of comparable magnitudes were consistently detected after each booster immunization. As previously reported in humans (26), we observed a striking correlation between the frequencies of Env-specific early plasmablasts and the ensuing IgG binding antibody titers (data not shown).

The longevity of humoral responses has been attributed to the persistence of long-lived plasma cells (LLPCs) in the bone marrow (28). We assessed the frequencies of Env-specific plasma cells in the bone marrow after each booster immunization (Fig. 3D and S3B). The highest frequency of Env-specific LLPCs was found in animals immunized with protein-NP (Fig. 3D). Importantly, the frequency of LLPCs increased with every successive immunization. Four animals each immunized with protein-NP and protein-alum were sacrificed at 9 to 10 weeks after the final immunization (Fig. 1B) to analyze the B cell responses in various tissues. Strikingly, the frequencies of the LLPC responses were higher not only in the bone marrow but also in the draining iliac and popliteal lymph nodes of animals immunized with protein-NP than in animals immunized with protein-alum (Fig. 3E and F), a finding similar to what we had observed previously in mice (13). Of note, plasma cell responses remained restricted to draining lymphoid tissues upon repeated immunization at the same anatomical site, with negligible Env-specific plasma cells being observed in nondraining lymphoid tissues (Fig. 3F).

**NP adjuvant induces higher Env-specific CD4+ T cell responses than alum.** We determined the frequencies of Env- and Gag-specific effector CD4+ T cell responses in peripheral blood and lymphoid organs. Env-specific and cytokine (interferon [IFN] gamma [IFN-γ], tumor necrosis factor [TNF], or interleukin-2 [IL-2])-secreting CD4+ T cell responses were found to be significantly higher upon immunization with protein-NP than upon immunization with the other immunization modalities after the final vaccination (Fig. S4A). These responses were also polyfunctional (i.e., they were capable of simultaneously eliciting the secretion of IFN-γ, TNF, and IL-2; Fig. S4B). Interestingly, the Env-specific responses elicited by VLPs were found to be polyfunctional after the primary immunization but less so after subsequent boosts. The Gag-specific responses were weaker than the Env-specific responses at each time point analyzed. Both Gag- and Env-specific CD8+ T cell responses were observed to be very low or barely detectable across all animals in the study (data not shown). Before challenge, higher frequencies of follicular T helper (TFH) cells and GC B cells were observed in local draining (popliteal and iliac) LNs than in nondraining LNs (Fig. S5). These data show that immunization with protein-NP significantly enhances the Env-specific effector CD4+ T cell responses in blood and at early time points induces TFH and GC cell responses in draining LNs comparable to those induced by alum.

**NP-adjuvanted vaccines induce robust and persistent mucosal antibody responses.** Antigen-specific antibodies at mucosal sites could offer protection against the mucosal transmission of HIV-1 (29). Accordingly, we evaluated the levels of the Env-specific IgG and IgA binding antibody responses in vaginal and rectal secretions at 2 weeks after each immunization and 1 month prior to challenge. Significantly higher Env-specific IgG and IgA responses were observed in the vaginal and rectal secretions of animals that received protein-NP both at 2 weeks after each immunization and at a prechallenge time point (4 weeks prior to challenge) (Fig. 4A to C). In contrast, Env-specific IgA responses in rectal secretions were only transiently elevated (Fig. 4D). A significant correlation between systemic and vaginal binding antibody (IgG and IgA) titers was observed in all immunized animals (Fig. 4E and F), suggesting a large
FIG 3 The NP adjuvant in the presence of the gp140 protein antigen significantly enhances Env-specific plasmablast responses in peripheral blood and persistent long-lived Env-specific plasma cells in bone marrow and draining lymph nodes in RMs. The frequency of Env-specific plasmablasts in peripheral blood and Env-specific plasma cells in the bone marrow and the secondary draining and nondraining lymphoid organs was determined by a B cell ELISPOT assay. (A) The peak plasmablast response in the peripheral blood of RMs was detected at day 4 after the boost immunizations. Env-specific IgG-, IgA-, and IgM-secreting B cells in wells from an ELISPOT assay plate for animals immunized with protein-NP at days 0, 4, and 7 after the first boost immunization in the study are shown. (B) Frequency of Env-specific IgG-, IgA-, and IgM-secreting plasmablasts per million PBMCs in one representative animal in the study. (C) Scatter plots of the magnitude of Env-specific IgG-secreting plasmablast responses at day 4 after each round of boost immunization in all treatment groups. (D) Scatter plots of the magnitude of Env-specific IgG-secreting plasma cells at 5 weeks following each round of boost immunization in all treatment groups. (E) Env-specific IgG-, IgA-, and IgM-secreting B cells in wells from an ELISPOT assay plate for one representative animal treated with protein-alum or NP adjuvant. (F) Frequencies of Env-specific IgG-secreting plasma cells per million total bone marrow cells in various draining and nondraining lymphoid organs at ~10 weeks after the final immunization. Horizontal bars, median responses. Statistical significance for the difference between treatment groups in panels C, D, and F was evaluated using a multigroup comparison by the Kruskal-Wallis test followed by the use of Dunn's correction. ****, P < 0.0001; *** , P < 0.001; **, P < 0.01; *, P < 0.05. BM, bone marrow.
contribution of serum-derived antibodies in mucosal secretions. A similar correlation between the serum and rectal IgG binding antibody responses was observed (data not shown). Interestingly, the correlations for the IgA responses outlined above primarily relied on the responses from animals immunized with protein and not VLPs. Of note, local plasma cells were not detected in the vaginal or rectal tissues of animals in groups 3 and 4 after they were sacrificed (data not shown), further supporting the likelihood that mucosal antibodies are derived from serum.

**NP-adjuvanted vaccines protect against vaginal acquisition of heterologous SIV in the presence of restrictive TRIM5α alleles.** To test the efficacy of humoral
immunity induced by vaccinations, the animals were intravaginally challenged with repeated exposures to low doses of a heterologous SIVsmE660 swarm (30–32). RMs were challenged once weekly for up to 12 exposures with SIVsmE660 (20,000 50% tissue culture infective doses [TCID50] or 0.5 to 1 50% animal infective doses [AID50]). The level of SIV RNA in plasma was monitored weekly, and an animal was considered infected if the viral loads were greater than 100 copies/ml in plasma for two consecutive weeks. The Kaplan-Meier curves shown in Fig. 5A depict the percentage of uninfected animals after each challenge. Approximately 50% of the unvaccinated naive animals were infected after four challenges, whereas six and seven challenges were required to infect 50% of the animals receiving protein-alum and VLP-alum, respectively. Ten challenges were required to infect 50% of the animals that received protein-NP, and even after 12 challenges, >50% of the animals receiving VLP-NP remained uninfected. However, statistical significance was not reached when the survival curves across treatment groups were compared with the survival curve for unvaccinated control animals. To elucidate the role played by individual adjuvants (NP versus alum), we then combined the data for all animals by adjuvant irrespective of the form of antigen for survival analysis. Greater than 50% of all NP adjuvant-treated animals survived after 12 intravaginal viral challenges, whereas ~27% of unvaccinated or alum-treated survived animals (P = 0.0786, log-rank test, for NP-adjuvanted versus unvaccinated animals) (Fig. 5B). Since select TRIM5α alleles may confer partial resistance to the SIVsmE660 challenge strain, we included that parameter in the evaluation.

FIG 5 The NP adjuvant mediates enhanced protection against a low-dose intravaginal challenge with heterologous SIVsmE660 in the presence of restrictive TRIM5α in RMs. A Kaplan-Meier survival curve analysis was performed after a series of 12 weekly intravaginal challenges. (A) Survival curves for all treatment groups in the study, including unvaccinated control animals. The numbers in parentheses represent the number of uninfected animals at the end of 12 challenges/total number of animals. (B) Survival curves for all animals that received NP or alum adjuvant irrespective of antigen in comparison with the survival curve for unvaccinated control animals. (C) Survival curves for all animals bearing restrictive alleles that received NP or alum adjuvant. Survival curves were compared using a log-rank (Mantel-Cox) test, and a P value of <0.05 was considered significant.
(30, 32). Animals carrying either restrictive or permissive TRIM5\(\alpha\) alleles were equally distributed in the treatment groups used in the study, as shown in Table S1. Mamu-A*001, Mamu-B*008, and Mamu-B*017- animals were also equally distributed among the treatment groups, even though these alleles have not previously been associated with resistance to the acquisition of the SIVsmE660 strain (30). The presence of restrictive TRIM5\(\alpha\) alleles was not associated with protection in unvaccinated animals (Fig. 5C). However, the presence of the restrictive TRIM5\(\alpha\) allele in animals immunized with the NP adjuvant appeared to significantly enhance resistance to the acquisition of virus \((P = 0.0286, \text{log-rank test})\). This observation did not translate to animals immunized with alum \((P = 0.3070, \text{log-rank test})\) when they were compared with unvaccinated animals. No protection was observed in animals carrying the permissive allele in the study (Fig. 5D). None of the vaccines appeared to significantly control viremia in the infected animals at either the peak (weeks 1 and 2) or the set point (week 12) (Fig. 56). These data suggest the ability of the NP adjuvant to enhance vaccine-mediated protection when it is combined with protein and VLP immunogens in the presence of restrictive antiviral alleles.

**Serum and vaginal IgG responses correlate with protection in animals immunized with protein and NP adjuvant.** The protective efficacy of 50% or greater observed in animals immunized with NP and either protein or VLP immunogens provided an opportunity to evaluate immune correlates. Env-specific serum IgG antibody responses in animals vaccinated with the protein-NP adjuvant were significantly higher \((P = 0.0317, \text{Mann-Whitney } t \text{ test})\) in uninfected animals than infected animals at prechallenge time points of week 37 (Fig. 6A) and week 41 and on the day of challenge (data not shown). No such differences were observed in the other immunization groups. The SIVmac239 Env-specific IgG binding antibody responses in the vaginal secretions of animals immunized with protein-NP adjuvant were also significantly higher \((P = 0.0159, \text{Mann-Whitney } t \text{ test})\) in uninfected animals than infected animals (Fig. 6B). The antibody responses elicited by the protein-NP adjuvant showed a significant association with a delay in the acquisition of virus infection, as indicated by Spearman’s correlation analysis, with the binding antibody responses to SIVmac239 Env, SIVsmE660 Env, and the SIV gp41 homologue HIV-2 gp36 and ADP activity (Fig. 6C to E). These associations held true irrespective of the presence of restrictive versus permissive TRIM5\(\alpha\) alleles (Fig. 6C to F and S7). Similar associations were not observed in the other immunization groups (data not shown). Finally, the Env-specific CD4\(^+\) T cell responses as well as the innate responses (the frequencies of monocyte and DC subsets), analyzed by flow cytometry at peak time points, also did not correlate with protection (data not shown).

**NP and alum adjuvants mediate distinct innate immune responses.** We have previously reported that different TLR agonists mediate distinct cellular and molecular signatures of early innate responses (33). Here, we compared the changes in the cellular and molecular signatures induced by NP and alum adjuvants. A significant expansion in the number of neutrophils in peripheral blood relative to that at the baseline was noted between 4 and 24 h postimmunization (Fig. 58A), while limited changes in the total number of peripheral blood mononuclear cells (PBMCs) were seen. However, among total PBMCs, a higher level of expansion of the number of lymphocytes was observed at days 7 and 14 in animals receiving the NP adjuvant than in those given alum (Fig. 5B). We developed a 12-color flow cytometry panel to evaluate the changes in the frequencies and the activation phenotypes of various individual cell types in peripheral blood at early time points postimmunization. We evaluated changes in monocyte subsets in RMs that included classical CD14\(^+\) CD16\(^-\) monocytes, intermediate CD14\(^+\) CD16\(^+\) monocytes, and nonclassical CD14\(^{dim/−}\) CD16\(^{+\pm}\) monocytes (Fig. 7A), as described before (11). The relative representation of CD14\(^+\) CD16\(^-\) monocytes was substantially increased after vaccination with NP adjuvants but not after vaccination with alum (Fig. 7B). Enhanced expression of CCR7, a chemokine receptor involved in homing to lymphoid organs, was observed on CD14\(^+\) CD16\(^-\) and CD14\(^+\) CD16\(^+\)
FIG 6 Binding antibody responses in serum and vaginal secretions in animals treated with protein-NP adjuvant significantly delay the onset of infection and correlate with protection. (A) SIVmac239 (left) and SIVsmE660 (right) Env-specific binding antibody response in the serum of infected and uninfected animals. $P$ values were calculated using a Mann-Whitney rank sum test. (B) SIVmac239 Env-specific binding antibody response in vaginal secretions of infected and uninfected animals. (C and D) Correlation of the binding antibody responses (SIVmac239 and SIVsmE660 Env-specific IgG) with the ability to delay or prevent infection. (E and F) Correlation of the binding antibody responses (HIV-2 gp36-specific IgG and ADP activity) with the ability to delay or prevent infection. (G) Correlation of the binding antibody responses (SIVmac239 Env-specific IgG) in vaginal secretions with the ability to delay or prevent infection. Spearman’s $r$ values and the associated $P$ values of significance are listed. $P$ values were not adjusted for multiple comparisons.
FIG 7  NP and alum adjuvants stimulate distinct early innate responses. The changes in cell frequency and activation induced by both adjuvants were measured using flow cytometry. (A) The flow cytometry gating strategy used to identify monocyte subsets, namely, the CD14+CD16− classical monocytes, CD14+CD16+ intermediate monocytes, and CD14−CD16− nonclassical subsets, is shown. Numbers in the flow cytometry plots (A and C) refer to cell frequencies that appear within the gate drawn to specify cell events. (B) Changes in monocyte subsets as a fraction of the total monocytes in peripheral blood after primary immunization. Blue lines, classical monocytes; brown lines, inflammatory monocytes; black lines, nonclassical monocytes. (C) The flow cytometry gating strategy used to identify changes in cell populations in peripheral blood is highlighted. pDCs were identified as CD14−CD20−CD3−CD8α−CD16−HLA-DR+CD11c+CD123−CD1c− cells. Two subsets of mDCs are highlighted: BDCA-1 mDCs (CD14−CD20−CD3−CD8α−CD16−HLA-DR+CD11c+CD123−CD11c− cells) and CD11c−mDCs (CD14−CD20−CD3−CD8α−CD16−HLA-DR+CD11c−CD1c+ cells). (D) Changes in pDC, mDC1, and mDC2 subsets in peripheral blood after primary immunization. Dotted lines, mean baseline frequencies of cell subsets in animals allocated to each treatment group. The statistical significance of the change in the frequencies of cell subsets in comparison with those at the baseline was determined using a paired nonparametric Wilcoxon matched-pairs signed-rank test. **, P < 0.01; *, P < 0.05. SSC, side scatter; FSC, forward scatter.
monocytes upon immunization with alum or NP adjuvants (Fig. S9). Minimal changes in the expression level of CCR7 on CD14<sup>dim</sup>CD16<sup>++</sup> monocytes were observed. In contrast, CD14<sup>dim</sup>CD16<sup>++</sup> monocytes had more prominent changes with CD86 expression at day 2 and day 4 in all animals except those immunized with protein and alum, though the change was most evident in animals immunized with protein-NP (Fig. S10). Only modest changes in CD86 expression on classical and intermediate monocytes were noted. The identification of various cell types in peripheral blood is detailed in the flow cytometry gating scheme shown in Fig. 7C. A significant expansion of the plasmacytoid DC (pDC) and myeloid DC (mDC) subsets with BDCA-1<sup>+</sup>CD11<sup>chi</sup>/neg cells was observed, with elevated numbers of mDCs persisting longer in NP-immunized animals than alum-immunized animals (Fig. 7D). Minimal change in CD11<sup>chi</sup>BDCA-1<sup>lo</sup>mDCs was observed (data not shown). The increased expression of CCR7 on all DC subsets (Fig. S11) and of CD86 only on mDC subsets (Fig. S12) was higher and more persistent when animals were immunized with the NP adjuvant than when they were immunized with alum. A significant decrease in the frequency of B cells in peripheral blood was observed in animals immunized with protein-NP, suggesting recruitment to lymphoid organs (Fig. S13). In contrast, a limited change in the frequencies of T cells, NK cells, and NK T cells was observed across all groups (Fig. S13).

**Blood transcriptional signatures that correlate with Env-specific antibody titers in vaginal secretions and protection against infection.** We next assessed the transcriptome changes in the PBMCs of animals immunized with the NP or alum adjuvant. Unsupervised principal component analysis (PCA) revealed that animals immunized with NP have a distinct gene expression profile at 24 h to 96 h postimmunization compared to the profile for animals immunized with alum (Fig. 8A). The NP adjuvant appeared to induce a larger transcriptional response than alum (Fig. 8B), as many genes were uniquely induced in groups immunized with the NP adjuvant (Fig. 8C, orange bars). Additionally, most of the genes which were differentially expressed in the alum-treated groups were also differentially expressed in the NP-treated groups (Fig. 8C, pink bars), suggesting that alum and NP may share an overlapping molecular mechanism of action during the initial hours postimmunization (Table S2).

We hypothesized that the TLR ligands in our NP formulation would trigger genes similar to those induced by the YF-17D vaccine (34). The levels of expression of several type I interferon and antiviral genes were found to be similar to the levels of expression of such genes induced by the YF-17D vaccine in humans (34) and were observed to be persistently higher in animals that received the NP adjuvant than in those immunized with alum (Fig. 8D). This suggests that the NP adjuvant induces a transcriptional program that is similar to that induced by live attenuated viruses.

One of the key findings of this study is the identification of an immunological correlate of protection; that is, in animals vaccinated with the NP adjuvant plus protein, the magnitude of the binding antigen-specific IgG response in the serum and in vaginal secretions on the day of challenge is correlated with protection against infection (Fig. 6). We wished to determine whether there were transcriptional signatures in the blood, induced within hours or days after vaccination, which correlated with protection and/or the immunological correlate. Thus, we analyzed gene signatures that were correlated with immunogenicity (vaginal IgG titers) and with protection in animals immunized with protein-NP (Fig. 9A). Although some genes were associated only with vaginal IgG titers (Fig. 9B, orange bars), hundreds of other genes were associated with both immunogenicity and protection outcome (Fig. 9B, purple bars, and Table S2). We next performed gene set enrichment analysis (GSEA) (35) of genes ranked by their correlation scores and by using blood transcription modules (BTMs) (36) as gene sets (Table S2). This analysis revealed that 4 different NK cell modules and 3 different T cell-related BTMs were positively correlated with protection as well as with vaginal antibody titers (Fig. 9C). Interestingly, this positive correlation was observed throughout the first several days, suggesting an ongoing role for NK cells and T cells in promoting antibody-mediated protection against infection. Furthermore, innate antiviral and type I IFN modules were positively correlated with protection against infection and vaginal
IgG titers, but only during the first 4 h (Fig. 9C). In addition, there was a striking but transient (only at 48 h) association between at least 4 BTMs related to monocytes, TLRs, and inflammatory signaling and neutrophils and both protection and vaginal IgG titers on the day of challenge. This transient association is consistent with the transient change in the relative representations of CD14$^+$ CD16$^-$ classical monocytes versus CD14$^+$ CD16$^+$ inflammatory monocytes, which was most striking at 2 days after vaccination (Fig. 7B), and may reflect the migration of specific subsets of monocytes from the blood to the lymphoid organs, where they may promote antibody responses (33). Taken together, these results demonstrate that the transcriptional signatures found to be induced in the blood within a few hours of vaccination with NP plus protein represent an early molecular correlate of immunogenicity and protection.

Finally, given our inability to identify any immunologic correlate of protection for animals immunized with VLP-NP, we wished to determine whether there were early transcriptional signatures that correlated with protection in animals immunized with VLP-NP. Our analysis revealed that, similar to the case in animals immunized with protein-NP, BTMs related to NK cells and T cells were positively correlated with protection (Fig. 9C).
FIG 9 Signatures of immunogenicity and protection. (A) We compared the baseline-normalized expression data from the initial 14 days after primary immunization with the vaginal antibody responses (signatures of immunogenicity) and protection outcomes (signatures of protection), which were defined after 40 weeks and almost 1 year after the primary immunization, respectively. (B) Genes whose baseline-normalized expression data were correlated with prechallenge vaginal SIVmac239 Env-specific IgG antibody titers (P < 0.01) and/or were different between infected and uninfected animals postchallenge (adjusted P value, <0.05; mean fold change, >1.25). Orange bars, genes found only in the signatures of immunogenicity; purple bars, genes found in both signatures. Selected genes are indicated by gray arrowheads. (C) BTMs associated with protection outcome and identified by GSEA (nominal P value, <0.05). Colors represent higher levels of expression in infected (blue) or uninfected (red) animals, with the lighter and darker shades of the two colors indicating lower and higher levels of expression, respectively.
However, unlike the case with protein-NP, this association was transient and observed only at 4 to 24 h. Furthermore, similar to the results obtained with the protein-NP group, there was a positive correlation between the expression of BTMs representing antiviral and type I IFN genes and protection, but this was observed only between 48 h and 14 days (Fig. 9C).

DISCUSSION

Our previous work has described the synthesis of poly(lactic-co-glycolic) acid (PLGA)-based NP-encapsulated TLR ligands and demonstrated their efficacy as vaccine adjuvants in mice (13). This work demonstrated the superior ability of such adjuvants to stimulate antigen-specific B and T cell responses compared with that of alum, which is the adjuvant most widely used today. A key question raised by our previous work was whether these NP-based adjuvants would demonstrate superior immunogenicity in nonhuman primates. In the current study, we have demonstrated that NP-encapsulated TLR ligands induce robust and persistent antibody responses against SIVmac239 Env immunogens in RMs. A key goal of this study was to compare the immunogenicity of the soluble gp140 Env protein immunogen with that of Env expressed on the surface of VLPs. Gag-Env pseudoviruses bearing native HIV Env trimers have been well characterized (19). The data in Fig. 2 demonstrate a greater magnitude of Env-specific antibody responses in animals vaccinated with soluble gp140 protein than in those vaccinated with VLPs. A caveat to this interpretation is that the ELISA used to measure Env-specific antibodies used the soluble gp140 protein and, hence, may have biased the results toward the detection of antibodies elicited by this form of the immunogen. While this is formally possible, it appears to be unlikely, since an alternative ELISA using concanavalin A-captured VLP Env yielded the same result (data not shown). Furthermore, serum from protein-immunized animals had greater neutralizing activity in assays dependent on live pseudovirus with native Env (Fig. 2F). Based on these data, we conclude that soluble gp140 immunogens are more immunogenic than VLPs when administered with the NP adjuvant. Finally, when the NP adjuvant was used with the soluble gp140 immunogen, it was also successful in mediating an Env-specific IgG response of a substantially larger magnitude than the IgA responses in serum (Fig. 1 and S1). Given that Env-specific IgA was reported to correlate negatively with protection, presumably by competing with Env-specific IgG (5), the ratio of IgG/IgA could have played a critical role in the protection observed in the current study.

The enhanced magnitude of Env-specific antibody responses was mirrored by a robust plasmablast response in the blood. Vaccination using either alum or NP adjuvant demonstrated that plasmablast responses in RMs appear rapidly (day 4) (Fig. 3) and earlier than previously reported in both RMs (37) and humans (26). Variable contraction of the immune response by day 7 has been observed in follow-up studies, depending on the nature, dose of immunogen, and adjuvant (unpublished data). Of note, greater than 75 to 80% of the plasmablast responses were Env specific (27). A striking finding was that NP adjuvants were also capable of inducing long-lived plasma cell responses in the bone marrow as well as in the draining iliac and popliteal LNs that persisted for several months after vaccination. This is consistent with the findings of our previous studies in mice, where NP adjuvant induced robust antibody responses and persistent germinal center and plasma cell responses in the draining LNs (13). Also, in additional experiments with an HIV-1-derived Env immunogen with NP encapsulating a novel TLR7/8 ligand with a fatty acid tail (which likely results in enhanced persistence of the adjuvant), the magnitude and durability (up to 1 year) of the Env-specific immune responses in macaques were significantly enhanced in comparison with those achieved with alum (unpublished data).

In other vaccine studies with nonhuman primates, the induction of mucosal IgA responses at sites of subsequent viral exposure has been associated with sterile protection, delayed acquisition of infection, or improved control of SIV or simian-human immunodeficiency virus (SHIV) infection (38–42). However, it is clear from passive immunization studies that IgG neutralizing antibodies in serum can also prevent rectal or vaginal transmission of SHIV in macaques (43–45). Some nonneutral-
izing IgG monoclonal antibodies, especially those to the gp41 immunodominant region, have also been found to confer resistance or reduce the number of transmitted/founder variants in vaginally challenged RMs (43, 46, 47). In this study, there was a striking induction and persistence of Env-specific IgG and IgA in both the serum and vaginal secretions of animals immunized with protein-NP. The anti-Env antibodies in vaginal secretions were concluded to have originated from serum because the levels were highly correlated (Fig. 4E and F), and no Env-specific antibody-secreting cells (ASCs) were detected in vaginal tissue (data not shown). As the levels of anti-Env IgG but not those of anti-Env IgA in these secretions were associated with protection, our data suggest that nonneutralizing serum IgG (but not IgA) that transudates into vaginal tissues and secretions may play a significant role in preventing vaginal virus transmission. On the other hand, we postulate that even greater protection might perhaps be achieved if both mucosal IgA and serum IgG antibody responses can be induced (48).

The protective efficacy of the NP-adjuvanted vaccines was assessed by repeated low-dose intravaginal challenge with the heterologous strain SIVsmE660. There was enhanced protection in animals that received the NP adjuvant relative to those that received alum (Fig. 5), which was most apparent in animals with TRIM5α restrictive alleles. Interestingly, the degree of protection was similar in animals that were immunized with either the protein or the VLP immunogen (Fig. 5). In such animals, protection was induced by immunization with NP adjuvants (but not with alum). This suggests a synergy between host restriction factors and vaccine-induced immune responses in mediating protection against SIV infection (32). The mechanistic basis of why such a synergy was observed only in animals receiving the NP adjuvant and not alum is unclear. One possible explanation, proposed by Letvin et al. (32), suggests that the higher levels of prechallenge serum (Fig. 1) and vaginal (Fig. 4) IgG in NP-adjuvanted animals could bind to SIV virions and decrease the effective inoculum available to infect the animal. As a consequence, the lowered residual load of infectious virions is susceptible to TRIM5α-mediated restriction. A role for type I IFN in the induction of innate restriction factors, such as TRIM5α, APOBEC3, and tetherin, is well documented (49). As such, a strong type I IFN response induced by the NP adjuvant (Fig. 8D) may have also partially contributed to protection. However, while the type I IFN-based antiviral responses stimulated by the NP adjuvant were higher and more persistent in peripheral blood than those stimulated by alum, it is unclear if the level of expression of innate host restriction factors in local (vaginal and rectal) tissues was also elevated. Future work should be aimed at systematically assessing this. Finally, a closer look at the innate restriction factors induced by adjuvants in human clinical trials may also yield additional insight into the development of adjuvants for HIV vaccines.

Partial or significant protection against a heterologous challenge with neutralization-sensitive or -resistant HIV variants as well as SIV/HIV chimeric challenge in vaccinated animals in comparison with that in unvaccinated controls has been demonstrated in RMs. Vaccine approaches in many of these studies included priming with plasmid DNA encoding SIV/HIV immunogens followed by the administration of viral vectors (modified vaccinia virus Ankara, adenovirus type 5) (31, 32, 50) or priming with viral vectors followed by recombinant protein boosts (39, 51–55). Consistent with the findings of these studies, analysis of correlates of protection in our current study revealed that the magnitude of the Env-specific binding antibody titers at week 37 prechallenge correlated strongly with the protection induced by immunization with protein-NP (Fig. 6). In contrast, no positive trends between antibody responses and protection outcome were observed in animals immunized with VLP-NP (data not shown). A modest yet significant association with increased acquisition of challenge virus was observed when correlating with the anti-SIVmac239-derived Env-specific binding antibody response (data not shown).

Flow cytometry- and systems-based approaches demonstrate that the innate immune responses and transcriptional signatures induced by NP adjuvants are very distinct from those induced by alum. We recently highlighted differences in the innate immune responses in peripheral blood and draining LNs induced by ligands for TLRs 4,
7/8, and 9 in nonhuman primates (33). A TLR7/8 ligand (R848) induced the mobilization, activation, and expansion of CD14<sup>+</sup> CD16<sup>+</sup> intermediate monocytes both in peripheral blood and in draining LNs. More recently, we have also demonstrated that CD14<sup>+</sup> CD16<sup>+</sup> intermediate monocytes infected with dengue virus (DENV) help with the differentiation of resting B cells into plasmablasts and enhanced immunoglobulin (IgG and IgM) production via the B cell-activating factor (BAFF), A proliferation-inducing ligand (APRIL), and IL-10 cytokines (56). Consistent with these observations, in our current study, the NP adjuvant led to the significant expansion of CD14<sup>+</sup> CD16<sup>+</sup> intermediate monocytes in peripheral blood at days 1 and 2 postvaccination in comparison with the findings for the alum adjuvant, where no such expansion was seen (Fig. 7B). Our data suggest that intermediate monocytes mobilized by the NP adjuvant could have contributed to the significantly higher level of expansion of Env-specific plasmablasts in peripheral blood and long-lived plasma cells in bone marrow in comparison with that achieved with alum (Fig. 3). Furthermore, the NP adjuvant was more potent than alum in its ability to activate monocyte subsets (Fig. S9 and S10) and DC subsets (Fig. S12 and S13).

Finally, NP adjuvants induced an antiviral type I IFN signature with temporal patterns similar to those induced by the live attenuated yellow fever vaccine (34). This analysis also revealed transcriptional signatures that correlate with both the immunogenicity (antigen-specific antibody titers in vaginal secretions on the day of challenge) and the protection induced by vaccination with protein-NP. The identification of early blood transcriptional signatures that correlate with the ensuing Env-specific antibody titers in vaginal secretions and protection against infection addresses an important problem in vaccinology, that is, how to identify blood biomarkers for mucosal immunity and protection against mucosal infection. However, the robustness of these signatures in their ability to predict protective immunity remains to be tested in an independent cohort of animals in future studies. Taken together, these results demonstrate that NP-encapsulated TLR ligands promote robust and durable antibody responses in RMs that contribute to protection against mucosal challenge and reveal hitherto unappreciated mechanisms by which such adjuvants drive the innate and adaptive response to vaccination.

MATERIALS AND METHODS

**Soluble Env and Gag immunogens.** Recombinant SIVmac239-derived Env gp140 protein purified from an HEK293 cell culture was procured from Immune Technology Corp., New York, NY, USA. The endotoxin level was certified to be <50 endotoxin units (EU)/mg (equivalent to <2.5 EU/dose in the study). Recombinant p55 Gag protein produced in insect cells was procured from Protein Sciences Corporation, Meriden, CT, USA. Protein was certified to have endotoxin levels of <10 EU/mg (<1 EU/dose in the study).

**Generation of SIVmac239 VLP-producing 293F cell lines.** 293F cells were transfected with pCDNA4/TO (Life Technologies) expressing SIVmac239 Gag. Stable transfectants were selected in zeocin (Life Technologies), and clonal populations were derived by limiting dilution. Following doxycycline induction, the levels of cellular and supernatant Gag and Env expression were established by Western blotting. Clones generating high yields of Gag-Env particles with complete cleavage of Env were selected for further use as a Gag VLP-producing cell line. This line was transfected with SIVmac239 Env in the vector pCDNAS/TO-puro (Life Technologies), and selection under puromycin was performed. Subsequent Gag and Env expression clones were derived as described above. SIV Gag-Env VLPs were harvested after 48 to 72 h of doxycycline induction for further characterization. VLPs were analyzed on 20 to 60% sucrose gradients, with fractions being harvested and concentrated for analysis by Western blotting. Cells expressing Gag-Env VLPs were fixed and prepared for transmission electron microscopy as previously described (18). Images were acquired on a Hitachi H-7500 transmission electron microscope.

**Procedures for purification of large-scale SIV VLP batches.** SIV Gag-Env-producing 293F cells were grown in 5 L spinner flasks and induced with doxycycline for 48 to 72 h. Supernatants were harvested, filtered through 0.45-μm-pore-size filters, and purified and concentrated by cross-flow (tangential) filtration using hollow-fiber cartridges and phosphate-buffered saline as the buffer.

**Adjuvants.** Alum (aluminum hydroxide; 2%; Alhydrogel) adjuvant was procured from InvivoGen. The alum dose was fixed at a 500-μg equivalent aluminum content as previously established in human studies (21, 22). Purified monophosphoryl lipid A (MPL) was procured from Avanti Lipids, AL, USA. The TLR7/8 agonist R848 was procured from Enzo Life Sciences. Poly(lactic-co-glycolic) acid (PLGA) was procured from Boehringer Ingelheim. Poly(vinyl alcohol) (PVA) was procured from Sigma-Aldrich. PLGA nanoparticles containing MPL and R848 were synthesized using an oil-in-water single emulsion followed by a solvent evaporation process as described before (13) with slight modifications. Briefly, the organic
phase containing PLGA with MPL and R848 was homogenized with 15 ml of a 5% (wt/vol) solution of PVA for 2 min using a Powergen homogenizer (Fisher Scientific) at a speed setting of 6. The oil-in-water emulsion was then solvent evaporated for 4 h at room temperature in a total volume of 100 ml. The nanoparticles that formed were collected by centrifugation and washed with 50 ml of 0.2-μm-pore-size filter-sterilized deionized water 2 times. The nanoparticle suspension was snap-frozen in liquid nitrogen and lyophilized using a FreeZone 2.5-liter benchtop lyophilizer (Labconco). Twenty milligrams of nanoparticles containing 50 μg of MPL and 750 μg of R848 was used in all NP immunizations.

Animals. Seventy-two female Indian RMs were used in the study. The animals were confirmed to be negative for SIV and simian T cell lymphotropic virus (STLV). The age range of the animals used in the study was 5 to 19 years. Animals were equally distributed among the treatment approaches on the basis of age and expression of the Mamu-A*001+, Mamu-B*008+, and Mamu-B*017+ alleles. TRIM5α genotyping was conducted as previously described (57), and restrictive (high) or permissive (moderate) alleles were also equally distributed among the groups. All animal procedures were performed in accordance with guidelines established by the Emory University School of Medicine Institutional Animal Care and Use Committee. Ten animals were assigned to each immunization group and used in challenge studies after four rounds of immunization. Two animals receiving treatment with VLP and alum and one animal given VLP and NP were withdrawn from the study for clinical reasons unrelated to the study. An additional 16 animals were allocated to groups receiving protein-alum and protein-NP, where 4 animals from each treatment group were sacrificed after each round of immunization to investigate organ-specific immune responses.

Immunization and sampling. Animals were immunized 4 times with ~8-week intervals between each round of immunization. Subcutaneous immunizations were carried out in the lower limb at a location behind the knee close to the popliteal LN. For VLP immunizations with alum, VLPs containing 50 μg of Env and 1.5 mg Gag were gently mixed with 500 μg of alum at room temperature. The mixture was maintained on ice until it was used for the immunizations, and the animals were immunized with a final volume of 1.2 ml. For VLP immunizations with NP adjuvant, NPs containing 50 μg of MPL and 750 μg of R848 were suspended in PBS. The mixture was briefly sonicated, vortexed, and mixed with VLPs before gentle mixing with NPs using low-speed vortexing. Animals were immunized with a final volume of 1.2 ml. For immunizations with protein and adjuvants, recombinant Env and Gag proteins were diluted in PBS and mixed with the alum or NP adjuvant as described above, and the final doses were 50 μg of Env and 50 μg of Gag. All immunizations and blood and mucosal tissue samplings were performed while the animals were under sedation, induced with 10 mg/kg of body weight ketamine. The animals were weighed each time that they were accessed for sampling.

Challenge stock of virus and intravaginal challenge. The RMs underwent a total of up to 12 challenges with SIVsmE660 (courtesy of Nancy Miller, NIAID), delivered intravaginally in a volume of 1 ml once a week. Each challenge dose contained virus at 2 × 10^5 TCID₅₀ and was titrated to represent an AI₅₀ of ~0.5 to 1. The virus stock was grown in pigtailed macaque primary cell cultures.

Analysis of anti-Env and anti-Gag plasmablast responses in blood and plasma cell responses in bone marrow. Enzyme-linked immunosorbent spot (ELISPOT) assays were performed as previously described (26, 58), with some modifications. Briefly, 96-well multiscreen HTS filter plates (catalog number MSHAN4850; Millipore) were coated overnight at 4°C with 10 μg/ml of anti-monkey IgG, IgA, or IgM (H&L goat antibody (Rockland) or with 2 μg/ml of recombinant SIV gp140 or Gag protein (Immune Technology Corp.) for enumeration of total or antigen-specific antibody-secreting cells (ASCs), respectively. The wells were washed 4 times with PBS–0.05% Tween 20 (PBS-T) and 4 times with PBS and blocked with complete RPMI 1640 medium (supplemented with 10% fetal bovine serum [FBS] and penicillin-streptomycin) for 2 h in a 5% CO₂ incubator at 37°C. Whole PBMC preparations or PBMC-derived sorted cells were diluted in complete RPMI 1640 medium, plated in serial 3-fold dilutions, and incubated overnight in a 5% CO₂ incubator at 37°C. The wells were washed 4 times with PBS and 4 times with PBS-T, followed by incubation with either anti-monkey IgG, IgA, or IgM-biotin-conjugated antibodies (Rockland), and diluted 1:1,000 in PBS–0.05% Tween 20–1% FBS solution (PBS-T-F) for 2 h at room temperature. The wells were again washed 4 times with PBS-T before addition of avidin D-horseradish peroxidase (HRP) (Vector Laboratories) diluted 1:1,000 in PBS-T-F. After a 3-h incubation at room temperature, the wells were washed 4 times with PBS-T and 4 times with PBS. Spots were developed with filtered 3-aminophenyl 9-ethylcarbazole (AEC) substrate (0.3 mg/ml AEC diluted in 0.1 M sodium acetate buffer [pH 5.0] containing a 1:1,000 dilution of 3% hydrogen peroxide). To stop the reaction, the wells were washed with water. Spots were documented and counted using an Immunospot cytotoxic T lymphocyte counter and Image Acquisition (v4.5) software (Cellular Technology). Once counted, the number of spots specific for each immunoglobulin isotype was reported as the number of either total or antigen-specific ASCs per million PBMCs.

Analysis of anti-Env IgG binding antibody responses in serum. Binding antibodies to SIVgp140 Env protein were assessed by enzyme-linked immunosorbent assay (ELISA) as described previously (59). Briefly, 96-well plates were coated overnight at 4°C with 1 μg/ml recombinant SIVmac239 or SIVsmE660 gp140 protein (Immune Technology Inc.) and then incubated with serial dilutions of heat-inactivated serum samples for 2 h followed by detection using HRP-conjugated goat anti-monkey IgG (1:10,000 dilution; Alpha Diagnostic) and 3,3’,5,5’-tetramethylbenzidine (TMB) substrate (KPL), followed by reading of the absorbance at 450 nm using a Bio-Tek Synergy H1 multimode microplate reader with Gen 5 (v2.0) software. A dilution series of an SIVmac239 or SIVsmE660 gp140-specific IgG standard with a known concentration was included in parallel, and antigen-specific concentrations relative to the standard were estimated and reported as the antigen-specific antibody quantity (in micrograms per milliliter).
PBMCs were used in assays unless otherwise specified. RPMI 1640 medium containing 1% sulfoxide only, (ii) a Gag peptide pool (1 to 125 peptides derived from SIVmac239) at a final concentration of 1 μg/ml, and the following: (i) a negative control with dimethyl sulfoxide only, (ii) a Gag peptide pool (1 to 125 peptides derived from SIVmac239) at a final concentration of 2 μg/ml. Each virus-serum series of uninfected wells was subtracted from the luminescence for each experimental well, and the average background luminescence for a serum and added to the plated TZM-bl cells in the presence of 40 μg/ml DEAE-dextran. The average background luminescence for a series of uninfected wells was subtracted from the luminescence for each experimental well, and infectivity curves were generated using GraphPad Prism (v6.0) software, where the values from the test wells were compared with the value from a well containing only virus (100% infectivity). Each virus-serum combination was tested at least twice independently in duplicate wells in each experiment.

PBMC stimulation and T cell intracellular cytokine staining (ICS) assay. Blood samples were collected in 4- or 8-mL cell preparation tubes (CPTs) containing 0.1 M sodium citrate (BD Biosciences). The CPTs were centrifuged at 1,500 g without brakes for 40 min at room temperature. Plasma was collected, and mononuclear cells were separated. ACK lysis buffer (Lanza, Walkersville, MD, USA) was used to lyse residual red blood cells, and the cells were washed with PBS before counting for use. Fresh PBMCs were used in assays unless otherwise specified. RPMI 1640 medium containing 1× L-glutamine was purchased from Corning Life Sciences/MediaTech Inc., Manassas, VA. The medium was supplemented to contain a final concentration of 10% FBS (Corning Life Sciences/Media Tech Inc., Manassas, VA), 10 mM HEPES, 1× minimal essential medium nonessential amino acids (Corning Life Sciences/Media Tech Inc., Manassas, VA), 1 mM sodium pyruvate (Lanza, Walkersville, MD, USA), 1 mM penicillin-streptomycin containing amphotericin B (Sigma Life Sciences, St. Louis, MO, USA), and 1× 2-mercaptoethanol (Gibco, Invitrogen, Carlsbad, CA, USA). PBMCs were stimulated for detection of cytokine production by T cells as described before (11). Briefly, 2× 10^5 cells were cultured in a 200-μL final volume in 5-mL polypropylene tubes (BD Biosciences, San Diego, CA, USA) in the presence of anti-CD28 (1 μg/ml), anti-CD49d (1 μg/ml), and the following: (i) a negative control with dimethyl sulfoxide only, (ii) a Gag peptide pool (1 to 125 peptides derived from SIVmac239) at a final concentration of 1 μg/ml, (iii) an Env peptide pool (1 to 110 peptides from SIVmac239) at a final concentration of 1 μg/ml.
expression at the baseline using the limma R package (68). Adjustments were performed for each treatment group and for each time point by comparison to the baseline value at each time point. Principal component analysis (PCA) was performed using the variance, leaving 9,800 genes for the subsequent analyses. Baseline-normalized expression data (here referred to “genes”) were considered. Considering all samples, we next removed the 30% of the genes with lowest mean level of expression and the 30% of the genes with the lowest variance, leaving 9,800 genes for the subsequent analyses. Baseline-normalized expression data (here referred to “fold change”) were obtained for each monkey by subtracting the value at the baseline from the corresponding value at each time point. Principal component analysis (PCA) was performed using the 5,000 genes with the highest absolute fold change across all samples. Differential expression analyses were performed for each treatment group and for each time point by comparison to the level of expression at the baseline using the limma R package (68) (adjusted P-value by the pairwise test, <0.05;
mean fold change, >1.25). Gene set enrichment analysis (GSEA; default parameters; nominal P value, <0.05) (35) was performed using the blood transcription modules (BTMs) (36) as gene sets. The signatures of immunogenicity at each time point were defined by the Spearman correlation between fold change values and the prechallenge vaginal IgG SIVmac239 Env titers (P < 0.01). The signatures of protection were defined for each time point by the limma test (adjusted P value, <0.05; mean fold change, >1.25) between the fold change values for infected and uninfected monkeys. GSEA was performed using genes preranked by either their Spearman correlation values (immunogenicity GSEA) or their log2 fold change values (protection outcome GSEA).

**TRIM5α genotyping.** Genomic DNA was isolated from lymphocytes from rhesus macaques with a QIAamp DNA kit (Qiagen) and sequenced for TRIM5α exons.

**Statistics.** Multigroup comparisons for all immunological readouts were performed using the nonparametric Kruskal-Wallis test followed by the use of Dunn’s correction. A log-rank Mantel-Cox test was used to compare the significance of changes in the frequencies of PBMCs in comparison with their baseline frequencies when longitudinal studies of innate responses were performed. A nonparametric Mann-Whitney test was used to compare the immune responses in uninfected and infected animals. Spearman’s correlation analysis was performed to assess the impact of immunological correlates. All analyses were performed using GraphPad Prism (v6.0) software. The P values determined in the study were not corrected for multiple comparisons. Note that the P values presented in the figures with multigroup comparisons are corrected (by the use of Dunn’s post hoc analysis) in a manner specific to the plots but are not corrected for the entire study.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/JVI.01844-16.

**TEXT S1,** PDF file, 2.7 MB.

**TEXT S2,** XLSX file, 1.5 MB.

**ACKNOWLEDGMENTS**

We thank all animal staff at the Yerkes National Primate Research Center at Emory University, especially Christopher Souder, Robert Sheffield, Stephanie Ehnhert, and Elizabeth Strobent, in helping out with the macaque study. We acknowledge Steve Bosingner, Nirav Patel, and Greg Tharp at the Yerkes Genomic Core for help with the processing the secretions and measuring mucosal antibodies. We thank Tianwei Yu for help with statistical analysis. We thank the CFAR Immunology/Emory Vaccine Center Flow Cytometry Core. We acknowledge the NIH AIDS Reagent Program for Gag and Env peptide pool reagents.

The CFAR Immunology/Emory Vaccine Center Flow Cytometry Core is supported by an NIH grant (P30 A050509). This work was supported by grants NIH PS1-R0000165 and PS1-OD011132 to the Yerkes National Primate Research Center. Studies were also supported by grants P01-AI096187 (principal investigator, Eric Hunter) and R01-AI58706 (principal investigator, Cynthia A. Derdeyn) from the National Institutes of Health and a Collaboration for AIDS Vaccine Discovery (CAVD) grant (principal investigator, Bali Pulendran) from the Bill and Melinda Gates Foundation.

**REFERENCES**


